ClinicalTrials.gg
RecruitingNCT07128927SIESTA-PUpdated Oct 26, 2026

Assessing the Feasibility of Web-based Insomnia Treatment Among Prostate Cancer Survivors

An interventional study of Sleep Healthy Using the Internet (SHUTi) and Patient education in Insomnia, sponsored by Georgetown University. Recruiting at 1 site in United States. Open to male participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Georgetown University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 26, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
21 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States — 149 open to participants now, 186 under way, 5 of them phase 3. Sleep Initiation and Maintenance Disorders · United States.

Planned enrollment
536th of 858
40 · median 60
Started
2025
with 56 others
No phase
580 of 907
110 open now
Primary completion
2027-09
later than 115 of 185 live
Registered
824th of 907
by date

Among the 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States, this one is the 536th largest by planned enrollment of the 858 interventional ones that give a count, is one of 57 that started in 2025, is one of 580 with no phase, reaches primary completion later than 115 of the 185 other live ones, and was the 824th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

149 of the 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States are open now. Recruiting first, the newest first:

144 more — sign in →

All 149 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 21 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States, or all of them as a file.
02

Study summary

This pilot study will recruit Black/African American prostate cancer survivors into a clinical trial and will randomize each person to 1 of 2 possible treatments - an internet-based treatment for insomnia called Sleep Healthy Using the Internet (SHUTi) or an educational website. SHUTi provides the treatment - cognitive behavioral therapy for insomnia - across 6 lessons, while the educational website is like an online patient brochure. The study will examine the feasibility of SHUTi to improve sleep and well-being among Black prostate cancer survivors. It will also examine whether SHUTi is acceptable to these survivors and will compare the effect of SHUTi versus the educational website on insomnia and non-insomnia patient-reported outcomes.

Read the detailed description

Insomnia is a risk factor for poor physical, cognitive, and psychosocial outcomes, including depression, anxiety, frailty, and diminished cognitive function, especially among cancer survivors. Although Cancer treatment, including androgen deprivation therapy, may increase insomnia symptoms and the prevalence of insomnia among prostate cancer survivors is estimated to be 25-39%. Prostate cancer has the highest incidence rate and second highest mortality rate among men in the U.S. with a highest burden of both incidence and mortality among Black men compared to men of other racial/ethnic groups. However, few studies have examined treatment of insomnia in this population. Insomnia is associated with greater symptom burden (i.e., multiple concurrent symptoms, such as depression, anxiety, fatigue, pain, cognition) among prostate cancer survivors, so treating insomnia may provide an opportunity to improve well-being in this population.

Cognitive Behavioral Therapy for Insomnia (CBT-I) has demonstrated substantial and persistent improvements in insomnia severity among cancer survivors such that the National Comprehensive Cancer Network (NCCN) recommends it "as the preferred treatment for insomnia." Trials to develop and test web-based and digital CBT-I interventions have shown non-inferiority to in-person administration by a trained therapist and increase availability of insomnia treatment to more patients. Recent NCCN guidelines note that improving sleep may provide additional benefits by resulting in less fatigue, better mood, better quality of life, and improved survival. However, to date, this accessible and interactive intervention has not been investigated among prostate cancer survivors.

This study uses the Sleep Healthy Using the Internet (SHUTi) program to provide CBT-I via the internet. SHUTi is self-administered and interactive with 6 weekly 45-60 minute sessions delivered over the course of 9 weeks. The program uses sleep diary data provided by each participant to tailor recommendations. Prostate cancer survivors participating in this pilot study will be randomized to receive access to SHUTi or to a patient education website. All participants will complete study visits and data collection, including sleep diaries and questionnaires, at baseline and post-intervention (10-12 weeks later).

03

Conditions studied

  • Insomnia

Keywords

  • insomnia
  • Sleep Healthy Using the Internet (SHUTi)
  • prostate cancer survivorship
  • cognitive behavioral therapy for insomnia
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥21 years
  • Self-identifies as Black/African American
  • Diagnosed with invasive prostate cancer (AJCC stages I-IV) within 5 years
  • Has not received surgery, chemotherapy, or radiation within the previous 3 months
  • Has a smart phone, tablet, or computer with reliable internet access or willing to attend a weekly study appointment and to complete a weekly phone call
  • Has insomnia symptoms (i.e., score ≥10 on the Insomnia Severity Index)
  • Able to read and understand English

Exclusion criteria

Exclusion Criteria:

  • Employed in an occupation where sleep restriction could be a harm to themselves or others
  • Actively employed in shift work
  • Diagnosed with a severe/major psychiatric disorder
  • Diagnosed with a seizure disorder or recently (≤12 months) experienced a seizure
  • Unable to consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Sleep Healthy Using the Internet (SHUTi)

    SHUTi provides 6 sessions of 45-60 minutes in length delivered over the course of 6-9 weeks. The program tailors recommendations based on sleep diary data provided by each participant.

    Behavioral: Sleep Healthy Using the Internet (SHUTi)

  • Placebo comparator
    Patient education

    Static information about insomnia provided on a patient education website

    Behavioral: Patient education

Interventions

  • BehavioralSleep Healthy Using the Internet (SHUTi)

    Web-based, self-administered, and interactive cognitive behavioral therapy for insomnia

    Also known as: Cognitive behavioral therapy for insomnia, CBT-i

  • BehavioralPatient education

    Website that describes insomnia, including factors that may increase or decrease insomnia symptoms, and provides information about addressing insomnia symptoms.

    Also known as: Sleep hygiene

06

What researchers measure

Primary outcomes

  1. Feasibility of study protocol

    Assessed via: * the percentage of survivors screened as eligible who consent to participate, * the percentage of actual vs. planned participants enrolled, and * the percentage of enrolled participants complete follow-up data collection

    Time frame: 10-12 weeks

  2. Acceptability of intervention

    Assessed via the theoretical framework of acceptability questionnaire (range: 5-35, higher score = greater acceptability)

    Time frame: 10-12 weeks

Secondary outcomes

  1. Efficacy of intervention

    Assessed via change in the Insomnia Severity Index score (range: 0-28, higher score = more insomnia symptoms) from baseline to post-intervention

    Time frame: 10-12 weeks

Other outcomes

  1. Impact on non-insomnia patient-reported outcomes

    Assessed via change in total number of reported non-insomnia patient-reported symptoms from baseline to post-intervention (range: 0-5, higher number = greater change in symptoms): * Functional Assessment of Cancer Therapy - Prostate (range: 0-156, higher score = better quality of life, score below baseline median = 1 PRO) * Male Depression Risk Scale short form (range: 0-154, higher score = greater symptoms of depression, score above baseline median = 1 PRO) * 18-item Memorial Anxiety Scale for Prostate Cancer (range: 0-54, higher score = greater anxiety symptoms, score above baseline median = 1 PRO) * Functional Assessment of Cancer Therapy - Cognitive Function - Perceived Cognitive Impairments (range: 0-72, higher score = better cognitive function, score below baseline median = 1 PRO) * Hot Flash Related Daily Interference Scale (range: 0-100, higher score = more interference, score above baseline median = 1 PRO)

    Time frame: 10-12 weeks

07

Study locations

1 of 1 sites recruiting
  • Georgetown Lombardi Comprehensive Cancer Center
    Washington D.C., District of Columbia 20003, United States
    Recruiting
    • Traci Bethea · Contactsiestap@georgetown.edu · 202-687-5367
    • Traci Bethea · Principal investigator
    • Paul Leger · Sub investigator
08

References and documents

Publications

  • Bai P. Application and Mechanisms of Internet-Based Cognitive Behavioral Therapy (iCBT) in Improving Psychological State in Cancer Patients. J Cancer. 2023 Jul 3;14(11):1981-2000. doi: 10.7150/jca.82632. eCollection 2023. PubMed 37497400 ↗
  • Gonzalez BD, Small BJ, Cases MG, Williams NL, Fishman MN, Jacobsen PB, Jim HSL. Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia. Cancer. 2018 Feb 1;124(3):499-506. doi: 10.1002/cncr.31024. Epub 2017 Oct 26. PubMed 29072790 ↗
  • Leger P, Frencher S Jr, Nauseef JT, Jones B, Bilen MA, Brown A Jr, Ullah A, McDevitt S, Tsao CK. A multi-perspective study assessing Black and African American participation barriers in prostate cancer clinical trials. Future Oncol. 2025 Apr;21(8):967-973. doi: 10.1080/14796694.2025.2467519. Epub 2025 Feb 24. PubMed 39992723 ↗
  • Ritterband LM, Thorndike FP, Gonder-Frederick LA, Magee JC, Bailey ET, Saylor DK, Morin CM. Efficacy of an Internet-based behavioral intervention for adults with insomnia. Arch Gen Psychiatry. 2009 Jul;66(7):692-8. doi: 10.1001/archgenpsychiatry.2009.66. PubMed 19581560 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Sep 2027, 21 months after the start.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 21 months is above that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2025
First posted
Aug 19, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Sep 1, 2027was Sep 2026
CompletionEst.
Sep 1, 2027was Sep 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 1, 2026→Sep 1, 2027
Oct 26, 2026
Study completion
Sep 1, 2026→Sep 1, 2027
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Primary completion Sep 1, 2026→Sep 1, 2027
    Study completion Sep 1, 2026→Sep 1, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07128927
Responsible party
Sponsor
First posted
Aug 19, 2025
Start date
Dec 1, 2025
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Traci Bethea
Contact
siestap@georgetown.edu
202-687-5367

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion